
VIGOQUIN-T | Tobramycin & Moxifloxacin Eye Drops
Product Description:
Composition:
Tobramycin Sulfate USP eq. to Tobramycin……………………………………..0.3% w/v
Moxifloxacin Hydrochloride IP eq. to Moxifloxacin………………………….0.5% w/v
Sterile aqueous vehicle……………………………………………………………………q.s.
Description:
Vigoquin-T is sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of ophthalmic infections.
Indication:
Vigoquin-T is indicated for the treatment of bacterial ocular infections (conjunctivitis, keratitis etc.) caused by bacterial strains susceptible to Tobramycin and Moxifloxacin.
Mechanism of Action:
Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30S ribosomal sub-unit, inhibiting bacterial protein synthesis. Whereas, Moxifloxacin inhibits Topioisomerase II and Topioisomerase IV, essential enzymes involved in DNA replication.
Clinical Pharmacology:
Tobramycin: In vitro studies have demonstrated that Tobramycin that is active against susceptible strains of the following microorganisms:
- Staphylococci, including S. aureous and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin resistant strains.
- Streptococci, including some of the Group A-beta-hemolytic species, some non-hemolytic species and some Streptococcus pneumoniae.
- Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabillis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.
Bacterial susceptibility studies demonstrated that in some cases, microorganisms resistant to Gentamicin retain susceptibility to Tobramycin
Moxifloxacin: Moxifloxacin exhibits in vitro minimal inhibitory concentrations (MICs) of 2 mcg/ml or less (systemic susceptible breakpoint) against most (= 90%) strains of the following ocular pathogens:
- Aerobic Gram-positive microorganisms: Bacteria belonging to the genus Staphylococcus and Streptococcus.
- Aerobic Gram-negative microorganisms: Bacteria belonging to the genus Acinetobacter, Enterobacter, Haemophilus, Klebsiella, Moraxella, Neisseria, Proteus, Pseudomonas etc.
- Anaerobic microorganisms: Clostridium perfringens, Peptostreptococcus anaerobius, Peptostreptococcus magnus, Peptostreptococcus micros, Peptostreptococcus prevotii.
- Other microorganisms: Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium kansasii, Mycobacterium marinum.
Contraindication:
Vigoquin-T is contraindicated in patients with known hypersensitivity to any of its components.
Warnings:
NOT FOR INJECTION. FOR EXTERNAL USE ONLY. If irritation persists or increases, discontinue the use and consult the physician. Do not touch the nozzle tip or other dispensing tip to any surface since this may contaminate the solution.
Use the solution within one month after opening the container. If the solution becomes cloudy or dark brown, it should be discarded.
Pregnancy:
Moxifloxacin is pregnancy category C drug while Tobramycin belongs to pregnancy category B. Vigoquin-T solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Geriatric Use:
No overall differences in safety and effectiveness have been observed between elderly and younger patients.
Adverse Reaction:
The most common adverse reactions of Moxifloxacin reported in 1-2% of patients were eye irritation, pyrexia and conjunctivitis. The most frequent adverse reactions to Tobramycin are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than 3 out of 100 patients.
Application and Administration:
Instill one or two drops into the affected eye(s) 4 times a day or as directed by the physician.
Storage:
Store below 25°C. Protect from light & moisture. Do not freeze.
Keep out if reach of children.
Presentation:
Vigoquin-T Eye Drops is available in a 5 ml container.